Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market

Fineline Cube Mar 10, 2026
Company Drug

Everest Medicines Launches Etrasimod in China – Next-Gen S1P Modulator Hits Market for Ulcerative Colitis

Fineline Cube Mar 10, 2026
Company Deals

Ouro Medicines Launches with $120M Series A Financing for CM336 Development

Fineline Cube Jan 13, 2025

Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.’s (HKG: 2162) CM336, has successfully launched...

Company Deals

Menarini Group Expands Oncology Pipeline with Insilico Medicine License

Fineline Cube Jan 13, 2025

Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal...

Company Deals

Zai Lab Secures Rights to Vertex’s Povetacicept in Key Asian Markets

Fineline Cube Jan 13, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced an exclusive collaboration and...

Company Deals

Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion

Fineline Cube Jan 13, 2025

US-based Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks with compatriot firm...

Company Deals

Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development

Fineline Cube Jan 13, 2025

US-based Light Horse Therapeutics Inc., a small molecule drug developer that recently emerged from the...

Company Deals

Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market

Fineline Cube Jan 13, 2025

South Korea’s Samsung Bioepis and Israel-based Teva Pharmaceutical (NYSE: TEVA) have entered into a license,...

Company Deals

Sepax Technologies Debuts on STAR Market with Soaring IPO Prices

Fineline Cube Jan 13, 2025

Sino-US firm Sepax Technologies Co., Inc. has successfully completed its initial public offering (IPO) on...

Company Drug

Bayer Files for Finerenone Approval in US and China for Heart Failure-Fineline Info & Tech

Fineline Cube Jan 13, 2025

Bayer AG (ETR: BAYN) has announced market filings with the US Food and Drug Administration...

Company Drug

Pfizer’s Sasanlimab Shows Positive Results in Phase III CREST Study

Fineline Cube Jan 13, 2025

US-based Pfizer Inc. (NYSE: PFE) has reported positive topline results from its pivotal Phase III...

Company Drug

NMPA Approves J&J’s FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma

Fineline Cube Jan 13, 2025

China’s National Medical Products Administration (NMPA) has approved Johnson & Johnson’s (J&J; NYSE: JNJ) FGFR...

Company Drug

Doma Biopharma Receives FDA Clearance for DM002 Phase I Study-Fineline Info & Tech

Fineline Cube Jan 13, 2025

China-based Doma Biopharmaceutical (Suzhou) Co., Ltd has announced that it has received clearance from the...

Company Drug

GSK’s Shingrix Prefilled Syringe Accepted for FDA Review

Fineline Cube Jan 13, 2025

UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has announced that a market filing for a prefilled syringe...

Policy / Regulatory

NHSA Launches Nationwide Self-Inspection Campaign on Medical Insurance Fund Usage

Fineline Cube Jan 13, 2025

China’s National Healthcare Security Administration (NHSA) released a notification last weekend, mandating designated medical institutions...

Policy / Regulatory

China’s NHSA Implements New Regulations for Medical Insurance Payment Qualifications

Fineline Cube Jan 13, 2025

China’s National Healthcare Security Administration (NHSA) has released the “Regulations on the Management of Medical...

Company

Shenzhen Oculgen Secures Over RMB 100 Million in Series A Funding

Fineline Cube Jan 11, 2025

Shenzhen Oculgen Biomedical Technology Co., Ltd. has successfully completed a Series A financing round, raising...

Company Drug

Fosun Pharmaceutical’s FCN-437c Accepted for NMPA Review for Breast Cancer Treatment

Fineline Cube Jan 11, 2025

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has announced that another market approval...

Company Drug

Hengrui’s SHR4640 Accepted for NMPA Review for Gout and Hyperuricemia Treatment

Fineline Cube Jan 11, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that a market filing for...

Company Deals

Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development

Fineline Cube Jan 11, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm...

Company Deals

Biocytogen and SOTIO Biotech Partner on Colorectal Cancer ADC Candidate SOT109

Fineline Cube Jan 11, 2025

China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing...

Company Deals

Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes

Fineline Cube Jan 11, 2025

Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...

Posts pagination

1 … 195 196 197 … 632

Recent updates

  • Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market
  • GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value
  • FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market
  • Everest Medicines Launches Etrasimod in China – Next-Gen S1P Modulator Hits Market for Ulcerative Colitis
  • FDA Advances Section 804 Drug Importation Program – States Meet Agency on Canadian Prescription Import Pathway
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Company Drug

Everest Medicines Launches Etrasimod in China – Next-Gen S1P Modulator Hits Market for Ulcerative Colitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.